國際特別演講

【學術講座+國際交流】111年10月6日(四) 上午8:00-10:00 

長庚大學<美國聖路易華盛頓大學職能治療系 Dr.Susan Stark特別演講>

● 講者：Susan Stark / 美國聖路易華盛頓大學職能治療系教授

● 題目：

(英文) The Home hazards removal program (HARP) study

(中文) 移除高齡者居家跌倒風險研究

由長庚大學健康老化研究中心於2022年9月5日下午邀請相關成員針對健康老化之相關議題進行探討，其中包含學術探討、臨床應用及產學應用交流等內容，其與會人員包含長庚大學健康老化研究中心人員及校內師生外，亦包含健康福祉伙伴學校教師及同仁。

The overarching theme of the congress is population ageing as a global phenomenon that is already changing the world, and the impact of population ageing on care needs and care policies in the future. In addition, the congress discusses the measures and policy tools needed to ensure high-quality care for older people.

The mid-term congress offers researchers interested in the above-mentioned topics an opportunity to present their research results in this multidisciplinary congress. Another aim of the congress is to offer researchers an opportunity to exchange ideas and strengthen existing research networks and build new ones. Third important aim of the congress is to provide an arena to develop ideas and research collaboration for the future. We invite contributions from researchers working within the CoE AgeCare and our collaborators, but welcome also contributions from research groups and researchers who are not affiliated to the CoE AgeCare.

The congress program includes invited speakers and thematic groups, and plenty of time for general discussions and smaller gatherings. Thematic groups include three topics: 1) population ageing and care needs and inequalities, 2) agency and self-determination of older people, 3) diversification, rehybridization and digitalisation of care work.

Congress website: https://events.tuni.fi/coeagecare2022congress/

時間: 2022/06/09 08:30-10:30

講者: Monica Reid (Ph.D. 2nd degree connection 2nd)

現職: Senior Director of Drug Product Development at Concentric Analgesics, Inc.

題目: Practical considerations for bringing a drug to clinical studies

Dr. Reid received her BS in Chemistry from North Carolina State University, her MS in Biotechnology from The Johns Hopkins University, and her Ph.D. in Transdermal Pharmaceutics from King’s College, London.  She has worked in the pharmaceutical industry for 20 years, starting at Shire Labs in analytical chemistry before transitioning to formulation development and pilot plant GMP manufacturing. She has worked both at several small pharmaceutical companies and large Contract Manufacturing Organizations as a formulation development scientist, ranging from preclinical/Phase 1 to commercial manufacturing, including packaging, labeling, and distribution.  Five compounds that she has developed have gone on to be commercially approved products; these included both NCEs and reformulations of existing oral immediate-release products to extended/controlled release/combination formulations.  Currently, she is the technical drug product lead and project manager at a small startup developing a sterile lyophilized product for injection.